Description

Zolpidem Tartrate

Zolpidem Tartrate is a high-purity, non-benzodiazepine hypnotic agent used in pharmaceutical formulations for the short-term treatment of insomnia. It acts as a selective agonist of the gamma-Aminobutyric acid (GABA-A) receptor complex at the benzodiazepine recognition site, enhancing inhibitory neurotransmission and promoting sleep onset with minimal residual sedation. Zolpidem Tartrate
• Is a pharmaceutical-grade hypnotic agent for oral dosage forms
• Is used in the short-term management of insomnia and sleep-onset disorders
• Exhibits rapid absorption and short elimination half-life for controlled sleep induction
• Is suitable for immediate-release, sublingual, and extended-release formulations
• Is manufactured under Good Manufacturing Practice (GMP) certified conditions
• Is supplied with complete regulatory documentation including Certificate of Analysis (CoA) and technical data
Zolpidem Tartrate is chemically designated as N,N,6-Trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide L-tartrate (2:1). It appears as a white to off-white crystalline powder, freely soluble in water, ethanol, and methanol, and stable under controlled storage conditions.
In pharmaceutical applications, Zolpidem Tartrate is used in:
• Oral immediate-release and extended-release tablets for sleep-onset and sleep-maintenance insomnia
• Sublingual formulations for rapid sleep induction and middle-of-the-night dosing
• Combination therapies for sleep disorders and circadian rhythm regulation
• Clinical research and development of non-benzodiazepine sedative-hypnotics
• Compounded preparations requiring precise dosage and dissolution control
Zolpidem Tartrate exerts its pharmacological activity through modulation of the GABA-A receptor, promoting chloride channel opening and neuronal hyperpolarization, leading to sedation and hypnotic effects. It is known for rapid onset and minimal next-day cognitive impairment when dosed appropriately.
CarboMer supplies Zolpidem Tartrate with control over assay, polymorphic form, residual solvents, and microbial content. The material meets pharmaceutical-grade standards and is suitable for regulated drug product manufacturing.
The material is packaged in sealed, light-protective, tamper-evident containers. Available in laboratory, pilot, and commercial-scale volumes. Minimum order quantities (MOQ), lead times, and documentation, including CoA and SDS are provided upon request.
Each batch is tested for identity (IR, HPLC), assay (anhydrous basis), optical purity, residual solvents, water content, and microbial limits. Certificates of Analysis (CoA), Safety Data Sheets (SDS), and full traceability documentation accompany every shipment.
As with all CarboMer central nervous system APIs, Zolpidem Tartrate is supported by formulation guidance, regulatory expertise, and dependable global supply to ensure safe, effective, and compliant pharmaceutical product performance.